Document Detail


Do current retinopathy of prematurity screening guidelines miss the early development of pre-threshold type 1 ROP in small for gestational age neonates?
MedLine Citation:
PMID:  17293789     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
PURPOSE: To investigate whether current UK retinopathy of prematurity (ROP) screening guidelines miss the early development of pre-threshold type 1 ROP in some neonates born small for gestational age (SGA) and consider if the guidelines should be changed.
METHODS: Data were collected on neonates of < or =31 completed weeks gestation and/or birth weight (BW) < or =1500 g born over a 37-month period. Babies who did not complete the screening programme in Cambridge and those with other ocular abnormalities were excluded. We compared the time course of ROP progression and the development of the early treatment for ROP pre-threshold ROP in relation to the gestational age and the BW of the babies.
RESULTS: A total of 105 neonates were included, 11 (10.5%) were born SGA (less than 9th centile of predicted BW). Of these 11, 2 (18.2%) had pre-threshold ROP at their first screen (median post-natal age (PNA) 6.5 weeks, median postmenstrual age (PMA) 33.5 weeks). No other neonate in this group developed pre-threshold ROP.Of the 94 other neonates, none had pre-threshold ROP at first screen (median PNA 7.1 weeks). Pre-threshold ROP developed in 12 (12.8%) of these babies between 8 and 12 (median 11.5) post-natal weeks, at a PMA of 33-38 (median 35.5) weeks.
CONCLUSION: Current UK ROP screening guidelines recommend first screening at 6-7 post-natal weeks. Our study suggests that pre-threshold type 1 ROP can develop before this especially in SGA babies. We suggest that screening should either start at 4 post-natal weeks in such babies, or be based on PMA rather than PNA, to allow timely laser therapy.
Authors:
A Misra; E Heckford; A Curley; L Allen
Related Documents :
12378579 - Second trimester trisomy 21 maternal serum marker screening. results of a countrywide s...
10807139 - Participation in maternal serum screening following screen positive results in a previo...
18243129 - Development of a chemical screening system using aqueorin-fused protein.
2456869 - Elevated maternal serum alpha-fetoprotein (msafp): interpretation and follow-up.
17429009 - A screening and intervention program aimed to reduce mortality and serious morbidity as...
17411619 - Cost-effectiveness model for first-trimester versus second-trimester ultrasound screeni...
24142539 - Pre-pregnancy care and pregnancy outcomes in type 1 diabetes mellitus: a comparison of ...
2632659 - Gamete intrafallopian transfer vs superovulation with intrauterine insemination for the...
24229579 - Maternal intake of vitamins a, e and k in pregnancy and child allergic disease: a longi...
Publication Detail:
Type:  Case Reports; Evaluation Studies; Journal Article     Date:  2007-02-09
Journal Detail:
Title:  Eye (London, England)     Volume:  22     ISSN:  0950-222X     ISO Abbreviation:  Eye (Lond)     Publication Date:  2008 Jun 
Date Detail:
Created Date:  2008-06-12     Completed Date:  2008-12-16     Revised Date:  2014-07-30    
Medline Journal Info:
Nlm Unique ID:  8703986     Medline TA:  Eye (Lond)     Country:  England    
Other Details:
Languages:  eng     Pagination:  825-9     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Cryotherapy
Disease Progression
Female
Humans
Infant, Newborn
Infant, Small for Gestational Age
Infant, Very Low Birth Weight
Laser Coagulation
Male
Neonatal Screening / standards*
Ophthalmoscopy
Practice Guidelines as Topic / standards*
Predictive Value of Tests
Retinopathy of Prematurity / complications,  diagnosis*,  surgery
Risk Factors
Severity of Illness Index

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Antioxidant activity of timolol on endothelial cells and its relevance for glaucoma course.
Next Document:  Viscocanalostomy versus trabeculectomy for primary open angle glaucoma: 4-year prospective randomize...